

Fergus J Couch

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/2116100/publications.pdf](https://exaly.com/author-pdf/2116100/publications.pdf)

Version: 2025-02-01

408

PR articles

28,795

PR citations

5596

79

PR h-index

5564

164

g-index

441

documents

34750

doc citations

4912

88

h-index

48591

citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic risk scores stratify breast cancer risk among women with benign breast disease. <i>Journal of the National Cancer Institute</i> , 2025, 117, 456-464.	4.6	3
2	Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience. <i>Clinical Breast Cancer</i> , 2025, 25, e211-e219.e2.	2.3	1
3	Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma <i>In Situ</i> of the Breast. <i>Clinical Cancer Research</i> , 2025, 31, 130-138.	6.8	8
4	Functional evaluation and clinical classification of BRCA2 variants. <i>Nature</i> , 2025, 638, 528-537.	37.9	29
5	Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer. <i>Npj Breast Cancer</i> , 2025, 11, .	6.4	1
6	Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking <i>ATM</i> to <i>TP53</i> Synthetic Essentiality. <i>Clinical Cancer Research</i> , 2025, 31, 1730-1745.	6.8	3
7	Trajectory of Global Mental Health and Global Physical Health in Breast Cancer Survivorship. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2025, 23, 141-146.	12.6	1
8	Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. <i>Nature Communications</i> , 2025, 16, .	13.7	2
9	Bipolar disorder comorbidity in breast cancer: impact of genetic risk and lifestyle characteristic on breast cancer outcomes. <i>Psychiatry Research</i> , 2025, 351, 116598.	3.1	0
10	Epithelial Abnormalities in the High-Risk Fallopian Tube of a Rare <i>TP53</i> / <i>BRCA2</i> Li-Fraumeni Syndrome Patient With Multiple Tumors. <i>JCO Precision Oncology</i> , 2025, , .	1.9	2
11	Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group. <i>Lancet Oncology</i> , The, 2025, 26, 911-923.	27.4	5
12	Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant. <i>Gynecologic Oncology</i> , 2025, 201, 44-52.	3.0	1
13	Germline Genetic Testing for Hereditary Breast and Ovarian Cancer: Current Concepts in Risk Evaluation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2024, 14, a041318.	6.6	5
14	Breast Cancer Polygenic Risk Score Influence on Risk-Reducing Endocrine Therapy Use: Genetic Risk Estimate (GENRE) Trial 1-Year and 2-Year Follow-up. <i>Cancer Prevention Research</i> , 2024, , .	1.5	4
15	Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain. <i>American Journal of Human Genetics</i> , 2024, 111, 584-593.	6.5	9
16	MRI Surveillance and Breast Cancer Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations. <i>JAMA Oncology</i> , 2024, 10, 493.	14.4	45
17	Bilateral Oophorectomy and All-Cause Mortality in Women With <i>BRCA1</i> and <i>BRCA2</i> Sequence Variations. <i>JAMA Oncology</i> , 2024, 10, 484.	14.4	33
18	Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization. <i>Breast Cancer Research and Treatment</i> , 2024, 206, 295-305.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Association of early menarche with breast tumor molecular features and recurrence. <i>Breast Cancer Research</i> , 2024, 26, .	4.8	11
20	Understanding the genetic complexity of puberty timing across the allele frequency spectrum. <i>Nature Genetics</i> , 2024, 56, 1397-1411.	25.2	34
21	Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years. <i>Cancers</i> , 2024, 16, 2494.	3.8	0
22	Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer. <i>Npj Breast Cancer</i> , 2024, 10, .	6.4	5
23	<i>BRCA1</i> , <i>BRCA2</i> , and Associated Cancer Risks and Management for Male Patients. <i>JAMA Oncology</i> , 2024, 10, 1272.	14.4	31
24	Advocate-BREAST: advocates and patients' advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025. <i>Archives of Public Health</i> , 2024, 82, .	2.6	6
25	Evidence-based recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA <i>BRCA1</i> and <i>BRCA2</i> Variant Curation Expert Panel. <i>American Journal of Human Genetics</i> , 2024, 111, 2044-2058.	6.5	63
26	<i>BRCA</i> -mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. <i>British Journal of Cancer</i> , 2024, 131, 1400-1414.	5.5	44
27	Madarosis Among Breast Cancer Survivors. <i>Clinical Breast Cancer</i> , 2024, 24, e757-e763.	2.3	1
28	Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2024, 33, 1490-1499.	1.1	5
29	Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline <i>ATM</i> sequence variants. <i>American Journal of Human Genetics</i> , 2024, 111, 2411-2426.	6.5	11
30	Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. <i>Molecular Cancer</i> , 2024, 23, .	29.2	2
31	Germline copy number variants and endometrial cancer risk. <i>Human Genetics</i> , 2024, 143, 1481-1498.	2.9	2
32	Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction. <i>Breast Cancer Research</i> , 2024, 26, .	4.8	11
33	Association of raloxifene and tamoxifen therapy with cognitive performance, odds of mild cognitive impairment, and brain MRI markers of neurodegeneration. <i>Cancer Medicine</i> , 2023, 12, 2805-2817.	2.6	4
34	Summary of the experiences, knowledge, medical management, and family communication of monoallelic <i>MUTYH</i> carriers. <i>Journal of Genetic Counseling</i> , 2023, 32, 342-350.	1.7	1
35	<i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects. <i>Clinical Cancer Research</i> , 2023, 29, 422-431.	6.8	17
36	The risks of cancer in older women with <i>BRCA</i> pathogenic variants: How far have we come?. <i>Cancer</i> , 2023, 129, 901-907.	4.0	6

#	ARTICLE	IF	CITATIONS
37	PDJ amplicon in triple negative breast cancer. <i>Scientific Reports</i> , 2023, 13, .	3.4	2
38	Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. <i>Genome Medicine</i> , 2023, 15, .	9.6	12
39	MacroH2A histone variants modulate enhancer activity to repress oncogenic programs and cellular reprogramming. <i>Communications Biology</i> , 2023, 6, .	4.4	15
40	Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	13.7	40
41	Functional and Clinical Characterization of Variants of Uncertain Significance Identifies a Hotspot for Inactivating Missense Variants in RAD51C. <i>Cancer Research</i> , 2023, 83, 2557-2571.	3.8	13
42	Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast. <i>Breast Cancer Research and Treatment</i> , 2023, 200, 217-224.	2.4	10
43	Association of the <i>CHEK2</i> c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. <i>Cancer Medicine</i> , 2023, 12, 16142-16162.	2.6	5
44	Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. <i>Breast Cancer Research and Treatment</i> , 2023, 201, 257-264.	2.4	18
45	ENIGMA <i>CHEK2</i> Project: A Comprehensive Study Identifies Functionally Impaired <i>CHEK2</i> Germline Missense Variants Associated with Increased Breast Cancer Risk. <i>Clinical Cancer Research</i> , 2023, 29, 3037-3050.	6.8	25
46	Germline Mutations in 12 Genes and Risk of Ovarian Cancer in Three Population-Based Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2023, 32, 1402-1410.	1.1	8
47	A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry. <i>Breast Cancer Research</i> , 2023, 25, .	4.8	12
48	Changes in amount and intensity of physical activity over time in breast cancer survivors. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	2.9	11
49	Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2023, 9, 1514.	14.4	34
50	Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Cancer Research Communications</i> , 2023, 3, 2420-2429.	2.8	0
51	Polygenic Risk Score Modifies Prostate Cancer Risk of Pathogenic Variants in Men of African Ancestry. <i>Cancer Research Communications</i> , 2023, 3, 2544-2550.	2.8	6
52	Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. <i>British Journal of Cancer</i> , 2023, 130, 269-274.	5.5	27
53	Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY. <i>Breast Cancer Research and Treatment</i> , 2023, 204, 237-248.	2.4	13
54	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	4.6	36

#	ARTICLE	IF	CITATIONS
55	Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Proband on Concomitant Risk to First-Degree Relatives. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 372-381.	1.1	4
56	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. <i>Genetics in Medicine</i> , 2022, 24, 119-129.	4.2	28
57	Rare germline copy number variants (CNVs) and breast cancer risk. <i>Communications Biology</i> , 2022, 5, .	4.4	12
58	CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival. <i>Cancers</i> , 2022, 14, 353.	3.8	4
59	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	3.0	56
60	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. <i>Breast Cancer Research</i> , 2022, 24, .	4.8	26
61	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. <i>Nature Communications</i> , 2022, 13, .	13.7	71
62	Breast Cancer Screening Strategies for Women With <i>ATM</i> , <i>CHEK2</i> , and <i>PALB2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2022, 8, 587.	14.4	83
63	A clinically compatible drug screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. <i>EMBO Molecular Medicine</i> , 2022, 14, .	7.1	29
64	Estrogen receptor beta repurposes EZH2 to suppress oncogenic NF κ B/p53 signaling in triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	6.4	16
65	Genome-wide and transcriptome-wide association studies of mammographic density phenotypes reveal novel loci. <i>Breast Cancer Research</i> , 2022, 24, .	4.8	23
66	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. <i>Scientific Reports</i> , 2022, 12, .	3.4	4
67	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	7
68	An integrative model for the comprehensive classification of BRCA1 and BRCA2 variants of uncertain clinical significance. <i>Npj Genomic Medicine</i> , 2022, 7, .	4.3	5
69	Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. <i>NAR Cancer</i> , 2022, 4, .	2.8	36
70	Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. <i>Pancreatology</i> , 2022, 22, 770-773.	0.7	1
71	Classification of <i>BRCA2</i> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay. <i>Clinical Cancer Research</i> , 2022, 28, 3742-3751.	6.8	16
72	Surveillance mammography after treatment for male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 693-698.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study. <i>Cancer Research</i> , 2022, 82, 3201-3208.	3.8	19
74	Rare germline variants in <i>PALB2</i> and <i>BRCA2</i> in familial and sporadic chordoma. <i>Human Mutation</i> , 2022, 43, 1396-1407.	4.5	8
75	Incorporating progesterone receptor expression into the PREDICT breast prognostic model. <i>European Journal of Cancer</i> , 2022, 173, 178-193.	4.9	17
76	Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. <i>British Journal of Sports Medicine</i> , 2022, 56, 1157-1170.	10.6	61
77	Assessment of small in-frame indels and C-terminal nonsense variants of <i>BRCA1</i> using a validated functional assay. <i>Scientific Reports</i> , 2022, 12, .	3.4	3
78	Copy number variants as modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> pathogenic variant carriers. <i>Communications Biology</i> , 2022, 5, .	4.4	12
79	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1105-1108.	4.6	8
80	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	4.6	54
81	Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake. <i>Cancer Prevention Research</i> , 2021, 14, 175-184.	1.5	16
82	Whole-exome sequencing of non- <i>BRCA1/BRCA2</i> mutation carrier cases at high-risk for hereditary breast/ovarian cancer. <i>Human Mutation</i> , 2021, 42, 290-299.	4.5	48
83	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 557-566.	2.4	34
84	<i>CYP3A7*1C</i> allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	5.5	8
85	Real-World Experiences With Yoga on Cancer-Related Symptoms in Women With Breast Cancer. <i>Global Advances in Health and Medicine</i> , 2021, 10, .	1.9	15
86	Association of mammographic density measures and breast cancer 'intrinsic' molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 215-224.	2.4	19
87	A case-only study to identify genetic modifiers of breast cancer risk for <i>BRCA1/BRCA2</i> mutation carriers. <i>Nature Communications</i> , 2021, 12, .	13.7	37
88	A Population-Based Study of Genes Previously Implicated in Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 440-451.	34.6	709
89	Survival from breast cancer in women with a <i>BRCA2</i> mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	5.5	20
90	Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. <i>Cancers</i> , 2021, 13, 1084.	3.8	14

#	ARTICLE	IF	CITATIONS
91	Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2021, 145, 44-52.	4.9	10
92	Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?. <i>Cancers</i> , 2021, 13, 2370.	3.8	8
93	First international workshop of the ATM and cancer risk group (4-5 December 2019). <i>Familial Cancer</i> , 2021, 21, 211-227.	1.4	18
94	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	4.2	29
95	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5628-5637.	6.8	50
96	PP2A and E3 ubiquitin ligase deficiencies: Seminal biological drivers in endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 162, 182-189.	3.0	13
97	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. <i>American Journal of Human Genetics</i> , 2021, 108, 1190-1203.	6.5	7
98	N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. <i>Journal of Clinical Medicine</i> , 2021, 10, 3313.	2.5	7
99	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. <i>Journal of Clinical Oncology</i> , 2021, 39, 3430-3440.	16.9	33
100	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 15-23.	2.4	7
101	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. <i>European Journal of Cancer</i> , 2021, 152, 68-77.	4.9	24
102	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. <i>Breast Cancer Research</i> , 2021, 23, .	4.8	19
103	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	5.5	18
104	Genetic insights into biological mechanisms governing human ovarian ageing. <i>Nature</i> , 2021, 596, 393-397.	37.9	343
105	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 623-642.	1.1	35
106	Association of a novel endometrial cancer biomarker panel with prognostic risk, platinum insensitivity, and targetable therapeutic options. <i>PLoS ONE</i> , 2021, 16, e0245664.	2.3	11
107	Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1429-1433.	4.6	34
108	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. <i>Scientific Reports</i> , 2021, 11, .	3.4	3

#	ARTICLE	IF	CITATIONS
109	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	3.8	48
110	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	4.0	117
111	A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients. <i>Genetics in Medicine</i> , 2020, 22, 407-415.	4.2	182
112	Functional characterization of 84 <i>PALB2</i> variants of uncertain significance. <i>Genetics in Medicine</i> , 2020, 22, 622-632.	4.2	52
113	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	25.2	166
114	Cancer Risks Associated With Germline <i>PALB2</i> Pathogenic Variants: An International Study of 524 Families. <i>Journal of Clinical Oncology</i> , 2020, 38, 674-685.	16.9	383
115	Classification of variants of uncertain significance in <i>BRCA1</i> and <i>BRCA2</i> using personal and family history of cancer from individuals in a large hereditary cancer multigene panel testing cohort. <i>Genetics in Medicine</i> , 2020, 22, 701-708.	4.2	37
116	Effect of Germline Mutations in Homologous Recombination Repair Genes on Overall Survival of Patients with Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 6505-6512.	6.8	40
117	Breastfeeding and the risk of epithelial ovarian cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	3.0	16
118	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	4.2	114
119	A Rare <i>TP53</i> Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. <i>Cancer Research</i> , 2020, 80, 3732-3744.	3.8	37
120	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.5	56
121	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	25.2	437
122	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1213-1221.	4.6	68
123	Prediction of the functional impact of missense variants in <i>BRCA1</i> and <i>BRCA2</i> with <i>BRCA-ML</i> . <i>Npj Breast Cancer</i> , 2020, 6, .	6.4	27
124	Germline <i>HOXB13</i> mutations p.G84E and p.R217C do not confer an increased breast cancer risk. <i>Scientific Reports</i> , 2020, 10, .	3.4	4
125	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. <i>Journal of Medical Genetics</i> , 2020, 57, 509-518.	3.8	37
126	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	14.4	61

#	ARTICLE	IF	CITATIONS
127	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, .	6.4	67
128	The Contribution of Germline Predisposition Gene Mutations to Clinical Subtypes of Invasive Breast Cancer From a Clinical Genetic Testing Cohort. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1231-1241.	4.6	87
129	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in <i>RAD51C</i> and <i>RAD51D</i> . <i>Journal of the National Cancer Institute</i> , 2020, 112, 1242-1250.	4.6	148
130	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	3.1	42
131	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 599-605.	1.1	8
132	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, .	13.7	35
133	Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study. <i>Supportive Care in Cancer</i> , 2020, 28, 5833-5838.	2.2	9
134	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020, 31, 745-759.	10.0	1,223
135	Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. <i>Genetics in Medicine</i> , 2019, 21, 71-80.	4.2	60
136	Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Proband's Susceptibility Gene Mutation Status. <i>Journal of the National Cancer Institute</i> , 2019, 111, 264-271.	4.6	12
137	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	2.9	15
138	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, .	6.4	42
139	Accuracy of self-reported cancer treatment data in young breast cancer survivors. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, .	2.5	5
140	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, .	3.4	6
141	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, .	13.7	106
142	Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. <i>Breast Cancer Research</i> , 2019, 21, .	4.8	39
143	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	5.5	22
144	Hereditary Cancer Syndromes—A Primer on Diagnosis and Management, Part 2: Gastrointestinal Cancer Syndromes. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1099-1116.	3.7	42

#	ARTICLE	IF	CITATIONS
145	Hereditary Cancer Syndromesâ€”A Primer on Diagnosis and Management. Mayo Clinic Proceedings, 2019, 94, 1084-1098.	3.7	54
146	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	4.5	38
147	Germline Genetic Testing for Breast Cancer Risk: The Past, Present, and Future. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, , 61-74.	4.5	57
148	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, .	13.7	116
149	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	5.5	62
150	Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. Journal of Biological Chemistry, 2019, 294, 5980-5992.	2.2	43
151	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 175, 443-449.	2.4	16
152	Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. Nature Communications, 2019, 10, .	13.7	58
153	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.5	989
154	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood, 2019, 133, 1130-1139.	4.2	38
155	Cancer susceptibility gene mutations in type I and II endometrial cancer. Gynecologic Oncology, 2019, 152, 20-25.	3.0	40
156	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1</i> / <i>BRCA2</i> Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	4.6	39
157	The <i>BRCA2</i> c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	4.5	20
158	Clinical testing of BRCA1 and BRCA2: a worldwide snapshot of technological practices. Npj Genomic Medicine, 2018, 3, .	4.3	56
159	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. Journal of the National Cancer Institute, 2018, 110, 1030-1034.	4.6	113
160	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. International Journal of Cancer, 2018, 143, 746-757.	4.3	27
161	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. Current Treatment Options in Cardiovascular Medicine, 2018, 20, .	0.5	9
162	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Medicine, 2018, 7, 1978-1987.	2.6	79

#	ARTICLE	IF	CITATIONS
163	Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. <i>American Journal of Human Genetics</i> , 2018, 102, 233-248.	6.5	74
164	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, .	3.4	57
165	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	4.9	16
166	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	6.9	80
167	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. <i>Journal of the National Cancer Institute</i> , 2018, 110, 855-862.	4.6	279
168	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	3.8	64
169	Identification of nine new susceptibility loci for endometrial cancer. <i>Nature Communications</i> , 2018, 9, .	13.7	265
170	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. <i>Nature Genetics</i> , 2018, 50, 968-978.	25.2	226
171	Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2401.	16.6	499
172	Current Approaches to Cancer Genetic Counseling Services for Spanish-Speaking Patients. <i>Journal of Immigrant and Minority Health</i> , 2018, 21, 434-437.	1.4	24
173	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. <i>Breast Cancer Research and Treatment</i> , 2018, 173, 667-677.	2.4	28
174	Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. <i>Pancreatology</i> , 2018, 18, 46-53.	0.7	10
175	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. <i>European Journal of Human Genetics</i> , 2017, 25, 432-438.	3.0	30
176	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2789-2799.	3.8	87
177	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. <i>Nature Genetics</i> , 2017, 49, 834-841.	25.2	514
178	Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1190.	14.4	559
179	Non- BRCA familial breast cancer: review of reported pathology and molecular findings. <i>Pathology</i> , 2017, 49, 363-370.	1.6	37
180	Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 421-431.	2.4	11

#	ARTICLE	IF	CITATIONS
181	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. <i>Npj Breast Cancer</i> , 2017, 3, .	6.4	130
182	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	25.2	482
183	Association analysis identifies 65 new breast cancer risk loci. <i>Nature</i> , 2017, 551, 92-94.	37.9	1,398
184	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	25.2	394
185	Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls. <i>Gynecologic Oncology</i> , 2017, 147, 375-380.	3.0	133
186	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017, 141, 1830-1840.	4.3	22
187	Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes. <i>Annals of Surgical Oncology</i> , 2017, 24, 3067-3072.	2.3	83
188	Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women. <i>Nature Communications</i> , 2017, 8, .	13.7	25
189	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	4.6	291
190	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	4.9	53
191	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. <i>International Journal of Molecular Sciences</i> , 2017, 18, 627.	4.4	18
192	Alcohol consumption and breast tumor gene expression. <i>Breast Cancer Research</i> , 2017, 19, .	4.8	31
193	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, .	4.8	45
194	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 167, 89-99.	2.4	95
195	From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. <i>Journal of Community Genetics</i> , 2017, 9, 209-215.	1.1	5
196	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	8.1	137
197	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS ONE</i> , 2016, 11, e0158801.	2.3	12
198	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016, 11, e0160316.	2.3	12

#	ARTICLE	IF	CITATIONS
199	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	4.3	53
200	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	3.8	204
201	Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. <i>Npj Genomic Medicine</i> , 2016, 1, .	4.3	78
202	Patient survival and tumor characteristics associated with <i>CHEK2</i> :p.I157T findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	48
203	Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	44
204	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	37
205	Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 117-131.	2.4	20
206	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	54
207	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	1.7	24
208	Five endometrial cancer risk loci identified through genome-wide association analysis. <i>Nature Genetics</i> , 2016, 48, 667-674.	25.2	90
209	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. <i>American Journal of Human Genetics</i> , 2016, 98, 801-817.	6.5	130
210	Male breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: pathology data from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> . <i>Breast Cancer Research</i> , 2016, 18, .	4.8	96
211	A Recurrent <i>ERCC3</i> Truncating Mutation Confers Moderate Risk for Breast Cancer. <i>Cancer Discovery</i> , 2016, 6, 1267-1275.	25.1	47
212	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating <i>IGFBP5</i> expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	2.9	34
213	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1503-1510.	1.1	80
214	rs2735383, located at a microRNA binding site in the 3'UTR of <i>NBS1</i> , is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016, 6, .	3.4	2
215	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	25.1	192
216	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	63

#	ARTICLE	IF	CITATIONS
217	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, .	13.7	103
218	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, .	13.7	88
219	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). <i>Scientific Reports</i> , 2016, 6, .	3.4	21
220	Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	66
221	The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk. <i>Breast Cancer Research</i> , 2016, 18, .	4.8	11
222	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	70.8	291
223	Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 3232-3238.	2.3	60
224	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	2.9	47
225	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 138-153.	3.3	19
226	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. <i>Human Molecular Genetics</i> , 2016, 25, 2256-2268.	2.9	122
227	No evidence that protein truncating variants in <i>BRIP1</i> are associated with breast cancer risk: implications for gene panel testing. <i>Journal of Medical Genetics</i> , 2016, 53, 298-309.	3.8	100
228	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	25.2	148
229	Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease. <i>Cancer Research</i> , 2016, 76, 749-761.	3.8	33
230	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 207-211.	1.1	125
231	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	3.0	20
232	Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. <i>Breast Cancer Research and Treatment</i> , 2016, 161, 575-586.	2.4	142
233	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2016, 161, 117-134.	2.4	20
234	RAD51B in Familial Breast Cancer. <i>PLoS ONE</i> , 2016, 11, e0153788.	2.3	29

#	ARTICLE	IF	CITATIONS
235	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015, 136, .	4.3	37
236	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. <i>Scientific Reports</i> , 2015, 5, .	3.4	39
237	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. <i>BMC Cancer</i> , 2015, 15, .	2.9	10
238	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, .	4.8	28
239	Common germline polymorphisms associated with breast cancer-specific survival. <i>Breast Cancer Research</i> , 2015, 17, .	4.8	29
240	A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density. <i>Breast Cancer Research</i> , 2015, 17, .	4.8	22
241	Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. <i>Frontiers in Oncology</i> , 2015, 5, .	2.6	22
242	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.3	39
243	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2015, 24, 3595-3607.	2.9	47
244	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 18-32.	3.3	25
245	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. <i>EBioMedicine</i> , 2015, 2, 681-689.	9.7	58
246	A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 517-523.	2.4	23
247	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. <i>Journal of Medical Genetics</i> , 2015, 52, 224-230.	3.8	36
248	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.5	81
249	A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. <i>Genetics in Medicine</i> , 2015, 17, 739-746.	4.2	26
250	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	25.2	243
251	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015, 47, 373-380.	25.2	573
252	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	2.9	106

#	ARTICLE	IF	CITATIONS
253	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	6.5	40
254	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	16.6	471
255	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, .	4.8	20
256	Dense and Nondense Mammographic Area and Risk of Breast Cancer by Age and Tumor Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 798-809.	1.1	49
257	Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. <i>Cancer Research</i> , 2015, 75, 2457-2467.	3.8	59
258	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	25.2	417
259	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	2.9	76
260	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. <i>BMC Medicine</i> , 2015, 13, .	7.1	57
261	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1680-1691.	1.1	25
262	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 1478-1492.	2.9	54
263	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. <i>British Journal of Cancer</i> , 2015, 114, 298-304.	5.5	9
264	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2015, 135, 137-154.	2.9	9
265	A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis. <i>PLoS ONE</i> , 2014, 9, e101488.	2.3	43
266	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	2.3	51
267	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.2	44
268	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	3.2	55
269	The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor. <i>Cell Reports</i> , 2014, 9, 1318-1332.	6.3	32
270	ER ⁺ : characterization, prognosis, and evaluation of treatment strategies in ER ⁺ -positive and -negative breast cancer. <i>BMC Cancer</i> , 2014, 14, .	2.9	62

#	ARTICLE	IF	CITATIONS
271	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, .	4.8	110
272	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, .	4.8	63
273	<i>CYP2B6</i> is associated with increased breast cancer risk. <i>International Journal of Cancer</i> , 2014, 134, 426-430.	4.3	31
274	Functional Assays for Analysis of Variants of Uncertain Significance in <i>BRCA2</i> . <i>Human Mutation</i> , 2014, 35, 151-164.	4.5	114
275	Two Decades After <i>BRCA</i> : Setting Paradigms in Personalized Cancer Care and Prevention. <i>Science</i> , 2014, 343, 1466-1470.	36.2	332
276	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93.	3.1	28
277	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	2.8	159
278	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. <i>Nature Communications</i> , 2014, 5, .	13.7	124
279	Exome sequencing identifies <i>FANCM</i> as a susceptibility gene for triple-negative breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15172-15177.	7.5	181
280	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. <i>Nature</i> , 2014, 514, 92-97.	37.9	620
281	Evidence that breast cancer risk at the 2q35 locus is mediated through <i>IGFBP5</i> regulation. <i>Nature Communications</i> , 2014, 5, .	13.7	110
282	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014, 23, 6034-6046.	2.9	13
283	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014, 45, 1630-1638.	2.3	287
284	Comparison of mRNA Splicing Assay Protocols across Multiple Laboratories: Recommendations for Best Practice in Standardized Clinical Testing. <i>Clinical Chemistry</i> , 2014, 60, 341-352.	1.1	100
285	Genetic variation at <i>CYP3A</i> is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014, 16, .	4.8	14
286	Candidate locus analysis of the <i>TERT</i> - <i>CLPTM1L</i> cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. <i>Human Genetics</i> , 2014, 134, 231-245.	2.9	35
287	Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2013, 132, 1201-1212.	4.3	102
288	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. <i>Breast Cancer Research</i> , 2013, 15, .	4.8	39

#	ARTICLE	IF	CITATIONS
289	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	6.5	104
290	Genetic Susceptibility to Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2013, 73, 2025-2030.	3.8	203
291	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	25.2	514
292	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	6.5	209
293	Genetic Alterations Associated With Progression From Pancreatic Intraepithelial Neoplasia to Invasive Pancreatic Tumor. <i>Gastroenterology</i> , 2013, 145, 1098-1109.e1.	0.9	186
294	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	25.2	1,020
295	A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 529-542.	2.4	18
296	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.2	114
297	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.2	261
298	Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. <i>PLoS Genetics</i> , 2013, 9, e1003284.	3.2	142
299	BRCA1/2 Sequence Variants of Uncertain Significance: A Primer for Providers to Assist in Discussions and in Medical Management. <i>Oncologist</i> , 2013, 18, 518-524.	3.4	85
300	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, .	13.7	107
301	Mammographic density and risk of breast cancer by age and tumor characteristics. <i>Breast Cancer Research</i> , 2013, 15, .	4.8	166
302	SoftSearch: Integration of Multiple Sequence Features to Identify Breakpoints of Structural Variations. <i>PLoS ONE</i> , 2013, 8, e83356.	2.3	41
303	BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. <i>Journal of Medical Genetics</i> , 2012, 49, 525-532.	3.8	113
304	Molecular Basis for the Association of Microcephalin (MCPH1) Protein with the Cell Division Cycle Protein 27 (Cdc27) Subunit of the Anaphase-promoting Complex. <i>Journal of Biological Chemistry</i> , 2012, 287, 2854-2862.	2.2	25
305	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	1.1	52
306	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, .	4.8	24

#	ARTICLE	IF	CITATIONS
307	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	25.2	271
308	Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 618-620.	3.8	50
309	Mutation screening of RAD51C in high-risk breast and ovarian cancer families. <i>Familial Cancer</i> , 2012, 11, 381-385.	1.4	19
310	Tex14, a Plk1-Regulated Protein, Is Required for Kinetochores-Microtubule Attachment and Regulation of the Spindle Assembly Checkpoint. <i>Molecular Cell</i> , 2012, 45, 680-695.	13.3	46
311	BRCA2 Localization to the Midbody by Filamin A Regulates CEP55 Signaling and Completion of Cytokinesis. <i>Developmental Cell</i> , 2012, 23, 137-152.	7.7	80
312	The Germline MLH1 K618A Variant and Susceptibility to Lynch Syndrome-Associated Tumors. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 264-273.	2.5	7
313	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012, 33, 1123-1132.	4.5	36
314	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 1119-1126.	2.4	10
315	No evidence for association of inherited variation in genes involved in mitosis and percent mammographic density. <i>Breast Cancer Research</i> , 2012, 14, .	4.8	3
316	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2012, 14, .	4.8	83
317	A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). <i>Human Mutation</i> , 2012, 33, 8-21.	4.5	206
318	Classification of missense substitutions in the BRCA genes: A database dedicated to Ex-UVs. <i>Human Mutation</i> , 2012, 33, 22-28.	4.5	67
319	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	4.5	35
320	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	2.3	52
321	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	2.9	156
322	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011, 43, 1210-1214.	25.2	296
323	Inactivation of Brca2 Promotes Trp53-Associated but Inhibits KrasG12D-Dependent Pancreatic Cancer Development in Mice. <i>Gastroenterology</i> , 2011, 140, 1303-1313.e3.	0.9	71
324	Exploring the link between MORF4L1 and risk of breast cancer. <i>Breast Cancer Research</i> , 2011, 13, .	4.8	26

#	ARTICLE	IF	CITATIONS
325	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, .	4.8	76
326	Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. <i>Nature Genetics</i> , 2011, 43, 185-187.	25.2	116
327	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , 2011, 130, 685-699.	2.9	19
328	Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. <i>Human Mutation</i> , 2011, 32, 678-687.	4.5	79
329	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	2.9	70
330	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 4693-4706.	2.9	73
331	Genetic Variation in <i>IGF2</i> and <i>HTRA1</i> and Breast Cancer Risk among <i>BRCA1</i> and <i>BRCA2</i> Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1690-1702.	1.1	19
332	Von Hippel-Lindau gene product directs cytokinesis: a new tumor suppressor function. <i>Journal of Cell Science</i> , 2011, 124, 2132-2142.	2.4	14
333	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. <i>PLoS Biology</i> , 2011, 9, e1001199.	5.0	100
334	The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. <i>Breast Cancer Research and Treatment</i> , 2011, 131, 347-350.	2.4	6
335	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. <i>Breast Cancer Research</i> , 2010, 12, .	4.8	86
336	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 195-203.	2.4	64
337	Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. <i>Familial Cancer</i> , 2010, 9, 495-502.	1.4	50
338	Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. <i>Human Mutation</i> , 2010, 31, E1484-E1505.	4.5	86
339	Linkage analysis of obesity phenotypes in pre- and post-menopausal women from a United States mid-western population. <i>BMC Medical Genetics</i> , 2010, 11, .	1.8	12
340	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	25.2	317
341	Association of Mitotic Regulation Pathway Polymorphisms with Pancreatic Cancer Risk and Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 251-257.	1.1	24
342	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. <i>PLoS Genetics</i> , 2010, 6, e1001183.	3.2	89

#	ARTICLE	IF	CITATIONS
343	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 2010, 7, e1000279.	8.1	826
344	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2mutation carriers. Breast Cancer Research, 2010, 12, .	4.8	27
345	Genetic variation in the estrogen metabolic pathway and mammographic density as an intermediate phenotype of breast cancer. Breast Cancer Research, 2010, 12, .	4.8	17
346	On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics, 2010, 19, 300-306.	3.0	118
347	Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus. PLoS Genetics, 2010, 6, e1001029.	3.2	85
348	Association of Breast Cancer Susceptibility Variants with Risk of Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3044-3048.	1.1	24
349	Polymorphic Variants in Hereditary Pancreatic Cancer Genes Are Not Associated with Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2549-2552.	1.1	10
350	No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. BMC Cancer, 2009, 9, .	2.9	16
351	Genome-wide association studies identify new breast cancer susceptibility genes. Current Breast Cancer Reports, 2009, 1, 131-138.	0.8	3
352	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics, 2009, 41, 585-590.	25.2	445
353	Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Research, 2009, 11, .	4.8	47
354	Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Research and Treatment, 2009, 119, 453-462.	2.4	24
355	Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Research and Treatment, 2009, 123, 661-677.	2.4	88
356	International variation in rates of uptake of preventive options in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. International Journal of Cancer, 2008, 122, 2017-2022.	4.3	320
357	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	6.5	267
358	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature, 2008, 451, 1116-1120.	37.9	1,021
359	Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Research, 2008, 10, .	4.8	44
360	Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter. Journal of Biological Chemistry, 2008, 283, 36249-36256.	2.2	30

#	ARTICLE	IF	CITATIONS
361	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. <i>PLoS Genetics</i> , 2008, 4, e1000054.	3.2	324
362	Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios. <i>Cancer Informatics</i> , 2008, 6, CIN.S618.	1.9	46
363	No association of TGFBI L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. <i>Breast Cancer Research and Treatment</i> , 2008, 115, 185-192.	2.4	12
364	The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 342-346.	1.1	257
365	<i>AURKA</i> F31I Polymorphism and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1416-1421.	1.1	36
366	Functional assays for BRCA1 and BRCA2. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 298-310.	2.6	49
367	A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer Predisposition Genes. <i>American Journal of Human Genetics</i> , 2007, 81, 873-883.	6.5	433
368	Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?. <i>Breast Cancer Research</i> , 2007, 9, .	4.8	63
369	Bilateral Prophylactic Oophorectomy and Bilateral Prophylactic Mastectomy in a Prospective Cohort of Unaffected BRCA1 and BRCA2 Mutation Carriers. <i>Clinical Breast Cancer</i> , 2007, 7, 875-882.	2.3	87
370	Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 221-228.	2.4	47
371	Control of BRCA2 Cellular and Clinical Functions by a Nuclear Partner, PALB2. <i>Molecular Cell</i> , 2006, 22, 719-729.	13.3	787
372	A genome wide linkage search for breast cancer susceptibility genes. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 646-655.	3.0	114
373	Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 185.	16.6	571
374	In Reply. <i>Journal of Clinical Oncology</i> , 2006, 24, 3709-3709.	16.9	0
375	A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. <i>Breast Cancer Research and Treatment</i> , 2006, 102, 237-247.	2.4	32
376	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2006, 101, 113-121.	2.4	525
377	Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. <i>Oncogene</i> , 2005, 24, 3652-3656.	6.5	69
378	Reply to Palacios et al., ERBB2 and MYC alterations in BRCA1- and BRCA2-associated cancers?. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 206-206.	3.0	0

#	ARTICLE	IF	CITATIONS
379	Effect of pregnancy as a risk factor for breast cancer in <i>BRCA1</i> / <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2005, 117, 988-991.	4.3	164
380	Functional Evaluation and Cancer Risk Assessment of <i>BRCA2</i> Unclassified Variants. <i>Cancer Research</i> , 2005, 65, 417-426.	3.8	106
381	Genetic Epidemiology of <i>BRCA1</i> . <i>Cancer Biology and Therapy</i> , 2004, 3, 509-514.	4.1	21
382	A candidate tumor suppressor <i>HtrA1</i> is downregulated in ovarian cancer. <i>Oncogene</i> , 2004, 23, 1636-1644.	6.5	164
383	The Role of <i>Tbx2</i> and <i>Tbx3</i> in Mammary Development and Tumorigenesis. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2004, 9, 109-118.	3.1	88
384	<i>ERBB2</i> , <i>TBX2</i> , <i>RPS6KB1</i> , and <i>MYC</i> alterations in breast tissues of <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 1-11.	3.0	50
385	The 17q23 Amplicon and Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 313-322.	2.4	127
386	Oral Contraceptives and the Risk of Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1773-1779.	4.6	325
387	<i>BRCA2</i> and Pancreatic Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2002, 31, 99-106.	1.0	45
388	Genetic heterogeneity in Peutz-Jeghers syndrome. <i>Human Mutation</i> , 2000, 16, 23-30.	4.5	127
389	<i>BRCA1</i> Facilitates Stress-induced Apoptosis in Breast and Ovarian Cancer Cell Lines. <i>Journal of Biological Chemistry</i> , 2000, 275, 33487-33496.	2.2	136
390	Induction of the <i>BRCA2</i> Promoter by Nuclear Factor- κ B. <i>Journal of Biological Chemistry</i> , 2000, 275, 35548-35556.	2.2	47
391	CLINICAL OPTIONS FOR WOMEN AT HIGH RISK FOR BREAST CANCER. <i>Surgical Clinics of North America</i> , 1999, 79, 1189-1206.	2.3	19
392	Stable Interaction between the Products of the <i>BRCA1</i> and <i>BRCA2</i> Tumor Suppressor Genes in Mitotic and Meiotic Cells. <i>Molecular Cell</i> , 1998, 2, 317-328.	13.3	559
393	Interactions between genetic and epidemiological factors influencing mammographic density. <i>American Journal of Epidemiology</i> , 0, , .	3.3	0
394	A Comparative Study of Quality of Life and Oncologic Outcomes in Premenopausal Women with Hormone Receptor-Positive Breast Cancer: Bilateral Oophorectomy vs. Gonadotropin-Releasing Hormone Agonist Therapy. <i>Cancers</i> , 0, 17, 2916.	3.8	0
395	Factors associated with sleep disturbance in breast cancer survivors over time. <i>Oncologist</i> , 0, 30, .	3.4	0
396	Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline <i>PALB2</i> sequence variants. <i>American Journal of Human Genetics</i> , 0, 112, 2266-2280.	6.5	1

#	ARTICLE	IF	CITATIONS
397	Factors associated with and patterns of alcohol intake during the first year of breast cancer survivorship. <i>Journal of Cancer Survivorship</i> , 0, , .	2.1	1
398	Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. <i>JAMA Oncology</i> , 0, 11, 1458.	14.4	0
399	Targeting CDK12 disrupts estrogen-receptor chromatin recruitment and ER-MED1 transcription in advanced ER+ breast cancer. <i>Journal of the National Cancer Institute</i> , 0, , .	4.6	1
400	Mutagenesis of the PALB2 WD40 domain identifies variants defective in interaction with BRCA2 and DNA repair. <i>Journal of Biological Chemistry</i> , 0, 301, 110835.	2.2	0
401	CHFR expression and sensitivity of breast cancer cells to antimetabolic agents in vitro and in the I-SPY trial. <i>Npj Breast Cancer</i> , 0, 11, .	6.4	0
402	Genome-wide association study of 398,238 women unveils seven loci associated with high-grade serous ovarian cancer. <i>Npj Genomic Medicine</i> , 0, 10, .	4.3	0
403	Plasma assay of methylated DNA markers detects recurrent metastatic breast cancer. <i>Npj Breast Cancer</i> , 0, 12, .	6.4	0
404	Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer. <i>Breast</i> , 0, 85, 104619.	2.3	0
405	BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes. <i>American Journal of Human Genetics</i> , 0, 112, 2902-2921.	6.5	0
406	Endometriosis in Carriers of a Pathogenic Variant in BRCA1 or BRCA2: A Descriptive Analysis of a Large Multicenter BRCA Carrier Cohort. <i>Current Oncology</i> , 0, 32, 675.	3.0	0
407	The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1. <i>Current Oncology</i> , 0, 32, 705.	3.0	0
408	Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer. <i>Science Translational Medicine</i> , 0, 18, .	12.5	0